Treatment of B-cell cancers with anti-CD70 antibody-drug conjugates
View Patent ↗Disclosed are anti-CD70 antibodies and derivatives thereof conjugated to cytotoxic therapeutic agents, as well as pharmaceutical compositions and kits comprising the antibody- and antibody derivative-drug conjugates. Also disclosed are methods, for the treatment of a CD70-expressing cancer, comprising administering to a subject the disclosed pharmaceutical compositions.
1. A method for the treatment of a CD70-expressing cancer of a B-cell lineage in a human subject, the method comprising:
administering to the subject, in an amount effective for the treatment thereof, an antibody-drug conjugate comprising an antibody that specifically binds to CD70, wherein:
(i) the drug is a cytotoxic agent, and
(ii) the antibody-drug conjugate is internalized into cells, where it exerts a therapeutic effect.
2. The method of claim 1 , wherein the antibody is a humanized antibody.
3. The method of claim 1 , wherein the antibody is a chimeric antibody.
4. The method of claim 1 , wherein the antibody is multivalent.
5. The method of claim 1 , wherein the cytotoxic agent is selected from the group consisting of an auristatin, a DNA minor groove binding agent, a DNA minor groove alkylating agent, an enediyne, a duocarmycin, a maytansinoid, and a vinca alkaloid.
6. The method of claim 1 , wherein the cytotoxic agent is an anti-tubulin agent.
7. The method of claim 6 , wherein the cytotoxic agent is AFP or MMAE.
8. The method of claim 1 , wherein the antibody is conjugated to the cytotoxic agent via a linker.
9. The method of claim 8 , wherein the linker is cleavable under intracellular conditions.
10. The method of claim 9 , wherein the cleavable linker is cleavable by an intracellular protease.
11. The method of claim 10 , wherein the linker comprises a dipeptide.
12. The method of claim 11 , wherein the dipeptide is val-cit or phe-lys.
13. The method of claim 9 , wherein the cleavable linker is hydrolyzable at a pH of less than 5.5.
14. The method of claim 13 , wherein the hydrolyzable linker is a hydrazone linker.
15. The method of claim 9 , wherein the cleavable linker is a disulfide linker.
16. The method of claim 1 , wherein the antibody blocks binding of CD70 to CD27.
17. The method of claim 1 , wherein the antibody is a mouse antibody comprising a heavy chain variable region having the amino acid sequence set forth in residues 20 to 137 of SEQ ID NO:2, and a light chain variable region having the amino acid sequence set forth in residues 21 to 132 of SEQ ID NO:12, or a chimeric or humanized form of the mouse antibody.
18. The method of claim 17 , wherein the antibody comprises H1, H2, H3, L1, L2 and L3 complementarity-determining regions having, respectively, the amino acid sequences set forth in SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10; SEQ ID NO:16, SEQ ID NO:18, and SEQ ID NO:20.
19. The method of claim 1 , wherein the antibody is a mouse antibody comprising a heavy chain variable region having the amino acid sequence set forth in residues 20 to 137 of SEQ ID NO:22, and a light chain variable region having the amino acid sequence set forth in residues 21 to 132 of SEQ ID NO:32, or a chimeric or humanized form of the mouse antibody.
20. The method of claim 19 , wherein the antibody is a humanized antibody comprising H1, H2, H3, L1, L2 and L3 complementarity-determining regions having, respectively, the amino acid sequences set forth in SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30; SEQ ID NO:36, SEQ ID NO:38, and SEQ ID NO:40, respectively.
21. The method of claim 1 , wherein the CD70-expressing cancer is a B-cell lymphoma.
22. The method of claim 21 , wherein the B-cell lymphoma is Burkitt's lymphoma.
23. The method of claim 21 , wherein the B-cell lymphoma is a diffuse large B-cell lymphoma.
24. The method of claim 1 , wherein the CD70-expressing cancer is a B cell leukemia.
25. The method of claim 24 , wherein the B cell leukemia is chronic lymphocytic leukemia.